Cargando…

Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide

BACKGROUND: Irritable bowel syndrome with diarrhea (IBS-D) is a chronic disorder of gut–brain interaction that negatively affects work productivity and health-related quality of life (HRQOL). IBS-D therapeutic options are limited and include loperamide, an over-the-counter μ-opioid receptor agonist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brenner, Darren M, Sayuk, Gregory S, Abel, Jessica L, Burslem, Kate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390934/ https://www.ncbi.nlm.nih.gov/pubmed/33769858 http://dx.doi.org/10.18553/jmcp.2021.27.4.469

Ejemplares similares

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study
por: Brenner, Darren M., et al.
Publicado: (2019)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea
por: Abel, Jessica L., et al.
Publicado: (2018)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
por: Liu, Rebecca, et al.
Publicado: (2020)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
por: Lacy, Brian E, et al.
Publicado: (2017)

A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers
por: Moshiree, Baha, et al.
Publicado: (2022)

Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal Activity
por: Anwer, Md. Khalid, et al.
Publicado: (2023)

Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome
por: Sayuk, Gregory S, et al.
Publicado: (2017)

Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
por: Qin, Di, et al.
Publicado: (2022)

Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
por: Anwer, Md. K., et al.
Publicado: (2017)

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
por: Chey, W. D., et al.
Publicado: (2017)

Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea
por: Buono, Jessica L., et al.
Publicado: (2017)

Differential Diagnosis of Chronic Diarrhea: An Algorithm to Distinguish Irritable Bowel Syndrome With Diarrhea From Other Organic Gastrointestinal Diseases, With Special Focus on Exocrine Pancreatic Insufficiency
por: Brenner, Darren M., et al.
Publicado: (2023)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Evaluation of Eluxadoline Effect on Cardiac Repolarization
por: Bonifacio, Laura, et al.
Publicado: (2018)

Secondary Prophylaxis of Docetaxel Induced Diarrhea with Loperamide: Case Report
por: Lee, Hee Yeon, et al.
Publicado: (2013)

A Potential Role for Stress-Induced Microbial Alterations in IgA-Associated Irritable Bowel Syndrome with Diarrhea
por: Rengarajan, Sunaina, et al.
Publicado: (2020)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)

Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-Analysis
por: Li, Su-Ting T, et al.
Publicado: (2007)

Episodic Memories Among Irritable Bowel Syndrome (IBS) Patients: An Important Aspect of the IBS Symptom Experience
por: Sayuk, Gregory S., et al.
Publicado: (2022)

Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome
por: Martoni, Christopher J, et al.
Publicado: (2023)

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
por: Andrews, Christopher N, et al.
Publicado: (2019)

Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
por: Colomier, Esther, et al.
Publicado: (2021)

Gut Microbiota-Based Therapies for Irritable Bowel Syndrome
por: Stern, Emily K, et al.
Publicado: (2018)

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Loperamide Overdose
por: Arnold, Casey, et al.
Publicado: (2019)

An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018)

Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
por: Li, Pingping, et al.
Publicado: (2020)

Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome
por: Zhan, Kai, et al.
Publicado: (2020)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change
por: Cash, Brooks D., et al.
Publicado: (2021)

Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial
por: Zheng, Hui, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pihqdumbs5ab1f7ogh4hgbfa83